Format

Send to

Choose Destination
Biomed Res Int. 2013;2013:740892. doi: 10.1155/2013/740892. Epub 2013 Feb 14.

Increasing hematopoietic stem cell yield to develop mice with human immune systems.

Author information

1
Regenerative Medicine Institute, Cedars-Sinai Medical Center, Room 361, Steven Spielberg Building, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA.

Abstract

Hematopoietic stem cells (HSCs) are unique in their capacity to give rise to all mature cells of the immune system. For years, HSC transplantation has been used for treatment of genetic and neoplastic diseases of the hematopoietic and immune systems. The sourcing of HSCs from human umbilical cord blood has salient advantages over isolation from mobilized peripheral blood. However, poor sample yield has prompted development of methodologies to expand HSCs ex vivo. Cytokines, trophic factors, and small molecules have been variously used to promote survival and proliferation of HSCs in culture, whilst strategies to lower the concentration of inhibitors in the culture media have recently been applied to promote HSC expansion. In this paper, we outline strategies to expand HSCs in vitro, and to improve engraftment and reconstitution of human immune systems in immunocompromised mice. To the extent that these "humanized" mice are representative of the endogenous human immune system, they will be invaluable tools for both basic science and translational medicine.

PMID:
23509770
PMCID:
PMC3586441
DOI:
10.1155/2013/740892
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Hindawi Limited Icon for PubMed Central
Loading ...
Support Center